dc.contributor.author
Klopfleisch, Robert
dc.contributor.author
Meyer, Anja
dc.contributor.author
Schlieben, Patricia
dc.contributor.author
Bondzio, Angelika
dc.contributor.author
Weise, Chris
dc.contributor.author
Lenze, Dido
dc.contributor.author
Hummel, Michael
dc.contributor.author
Einspanier, Ralf
dc.contributor.author
Gruber, Achim D
dc.date.accessioned
2018-06-08T03:08:56Z
dc.date.available
2012-10-26
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/14580
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-18772
dc.description.abstract
Background Canine mast cell tumor proliferation depends to a large extent on
the activity of KIT, a tyrosine kinase receptor. Inhibitors of the KIT
tyrosine kinase have recently been introduced and successfully applied as a
therapeutic agent for this tumor type. However, little is known on the
downstream target genes of this signaling pathway and molecular changes after
inhibition. Results Transcriptome analysis of the canine mast cell tumor cell
line C2 treated for up to 72 hours with the tyrosine kinase inhibitor
masitinib identified significant changes in the expression levels of
approximately 3500 genes or 16% of the canine genome. Approximately 40% of
these genes had increased mRNA expression levels including genes associated
with the pro-proliferative pathways of B- and T-cell receptors, chemokine
receptors, steroid hormone receptors and EPO-, RAS and MAP kinase signaling.
Proteome analysis of C2 cells treated for 72 hours identified 24 proteins with
changed expression levels, most of which being involved in gene transcription,
e.g. EIA3, EIA4, TARDBP, protein folding, e.g. HSP90, UCHL3, PDIA3 and
protection from oxidative stress, GSTT3, SELENBP1. Conclusions Transcriptome
and proteome analysis of neoplastic canine mast cells treated with masitinib
confirmed the strong important and complex role of KIT in these cells.
Approximately 16% of the total canine genome and thus the majority of the
active genes were significantly transcriptionally regulated. Most of these
changes were associated with reduced proliferation and metabolism of treated
cells. Interestingly, several pro-proliferative pathways were up-regulated,
which may represent attempts of masitinib treated cells to activate
alternative pro-proliferative pathways. These pathways may contain
hypothetical targets for a combination therapy with masitinib to further
improve its therapeutic effect.
de
dc.format.extent
[26 S.]
dc.rights.uri
http://creativecommons.org/licenses/by/2.0/
dc.subject
Mast cell tumor
dc.subject
Tyrosine kinase inhibition
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::630 Landwirtschaft
dc.title
Transcriptome and proteome analysis of tyrosine Kinase inhibitor treated
canine mast cell tumour cells identifies potentially kit signaling-dependent
genes.
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
BMC Vet Res. 2012 Jun 29;8(1):96
dcterms.bibliographicCitation.doi
10.1186/1746-6148-8-96
dcterms.bibliographicCitation.url
http://www.biomedcentral.com/1746-6148/8/96
refubium.affiliation
Veterinärmedizin
de
refubium.affiliation.other
Institut für Tierpathologie
refubium.mycore.fudocsId
FUDOCS_document_000000014873
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000002131
dcterms.accessRights.openaire
open access